Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

The successful return of psychedelics to psychiatry.

Kleber HD.

J Psychopharmacol. 2016 Dec;30(12):1211. No abstract available.

PMID:
27909172
2.

Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates Than Newer 'Medicalized' Programs.

Williams AR, Olfson M, Kim JH, Martins SS, Kleber HD.

Health Aff (Millwood). 2016 Mar;35(3):480-8. doi: 10.1377/hlthaff.2015.0528.

3.

Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.

Dakwar E, Kleber HD.

J Subst Abuse Treat. 2015 Jun;53:60-3. doi: 10.1016/j.jsat.2015.01.004. Epub 2015 Jan 15.

PMID:
25819700
4.

Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.

Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH; Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership.

Pain. 2013 Nov;154(11):2287-96. doi: 10.1016/j.pain.2013.05.053. Epub 2013 Jun 20. Review.

5.

Physicians and medical marijuana.

Kleber HD, DuPont RL.

Am J Psychiatry. 2012 Jun;169(6):564-8. doi: 10.1176/appi.ajp.2012.12030373. No abstract available.

PMID:
22684592
6.

Improving temporal efficiency of outpatient buprenorphine induction.

Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD.

Am J Addict. 2011 Sep-Oct;20(5):397-404. doi: 10.1111/j.1521-0391.2011.00153.x. Epub 2011 Jul 18.

7.

Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment.

Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, Kumar D, Van Heertum R, Kleber HD, Nunes E.

Am J Psychiatry. 2011 Jun;168(6):634-41. doi: 10.1176/appi.ajp.2010.10050748. Epub 2011 Mar 15. Erratum in: Am J Psychiatry. 2011 May;168(5):553.

8.

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD.

Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.

9.

Dopamine type 2/3 receptor availability in the striatum and social status in human volunteers.

Martinez D, Orlowska D, Narendran R, Slifstein M, Liu F, Kumar D, Broft A, Van Heertum R, Kleber HD.

Biol Psychiatry. 2010 Feb 1;67(3):275-8. doi: 10.1016/j.biopsych.2009.07.037. Epub 2009 Oct 6.

10.

Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion.

Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, Slifstein M, Van Heertum R, Kleber HD.

Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1. Erratum in: Am J Psychiatry. 2009 Nov;166(11):1299.

11.

Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine.

Martinez D, Slifstein M, Narendran R, Foltin RW, Broft A, Hwang DR, Perez A, Abi-Dargham A, Fischman MW, Kleber HD, Laruelle M.

Neuropsychopharmacology. 2009 Jun;34(7):1774-82. doi: 10.1038/npp.2008.235. Epub 2009 Jan 28.

12.

Methadone maintenance 4 decades later: thousands of lives saved but still controversial.

Kleber HD.

JAMA. 2008 Nov 19;300(19):2303-5. doi: 10.1001/jama.2008.648. No abstract available.

PMID:
19017918
13.

Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis.

Yu E, Miotto K, Akerele E, O'Brien CP, Ling W, Kleber H, Fischman MW, Elkashef A, Herman BH, Al-Ghananeem AM.

Am J Drug Alcohol Abuse. 2008;34(5):611-6. doi: 10.1080/00952990802308122.

PMID:
18821454
14.

A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman MW, Collins J, McSherry F, Boardman K, Davies DK, O'Brien CP, Ling W, Kleber H, Herman BH.

Drug Alcohol Depend. 2008 Sep 1;97(1-2):158-68. doi: 10.1016/j.drugalcdep.2008.04.002. Epub 2008 May 27.

15.

Reducing opioid. analgesic abuse: models for successful collaboration among government, industry and other key stakeholders.

Smith MY, Kleber HD, Katz N, Houck LK, Sabo A.

Drug Alcohol Depend. 2008 May 1;95(1-2):177-81. No abstract available.

PMID:
18484109
16.

Dextromethorphan and quinidine combination for heroin detoxification.

Akerele E, Bisaga A, Sullivan MA, Garawi F, Comer SD, Thomas AA, Nunes EV, Kleber HD.

Am J Addict. 2008 May-Jun;17(3):176-80. doi: 10.1080/10550490802019543.

17.

Use of dronabinol for cannabis dependence: two case reports and review.

Levin FR, Kleber HD.

Am J Addict. 2008 Mar-Apr;17(2):161-4. doi: 10.1080/10550490701861177. Review.

18.
19.

Abuse of buprenorphine in the United States: 2003-2005.

Smith MY, Bailey JE, Woody GE, Kleber HD.

J Addict Dis. 2007;26(3):107-11.

PMID:
18018814
20.

Insula damage and quitting smoking.

Vorel SR, Bisaga A, McKhann G, Kleber HD.

Science. 2007 Jul 20;317(5836):318-9; author reply 318-9. No abstract available.

PMID:
17641181

Supplemental Content

Loading ...
Support Center